The anti‐mitotic agents PTC‐028 and PTC596 display potent activity in pre‐clinical models of multiple myeloma but challenge the role of BMI‐1 as an essential tumour gene-Reference-Cited by-同舟云学术

The anti‐mitotic agents PTC‐028 and PTC596 display potent activity in pre‐clinical models of multiple myeloma but challenge the role of BMI‐1 as an essential tumour gene

Published:2020-03-30 Issue:6 Volume:190 Page:877-890
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br. J. Haematol.

Author:

Bolomsky Arnold¹^ORCID,Muller Joséphine²,Stangelberger Kathrin¹,Lejeune Margaux²,Duray Elodie²,Breid Helene¹,Vrancken Louise²,Pfeiffer Christina¹,Hübl Wolfgang³,Willheim Martin³,Weetall Marla⁴,Branstrom Art⁴,Zojer Niklas¹,Caers Jo²,Ludwig Heinz¹^ORCID

Affiliation:

1. Department of Medicine I Wilhelminen Cancer Research Institute Wilhelminenspital Vienna Austria

2. Laboratory of Hematology GIGA‐I3 University of Liège Liège Belgium

3. Department of Laboratory Medicine Wilhelminenspital Vienna Austria

4. PTC Therapeutics Inc South Plainfield NJ USA

Funder

International Myeloma Foundation

Publisher

Wiley

Subject

Hematology

Link